1. Home
  2. GDO vs ARMP Comparison

GDO vs ARMP Comparison

Compare GDO & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Global Corporate Defined Opportunity Fund Inc.

GDO

Western Asset Global Corporate Defined Opportunity Fund Inc.

HOLD

Current Price

$9.72

Market Cap

80.2M

Sector

Finance

ML Signal

HOLD

Logo Armata Pharmaceuticals Inc.

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$3.66

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDO
ARMP
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.2M
199.7M
IPO Year
2009
1996

Fundamental Metrics

Financial Performance
Metric
GDO
ARMP
Price
$9.72
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $17.50
AVG Volume (30 Days)
69.6K
★ 288.0K
Earning Date
01-01-0001
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.33
$3.09
52 Week High
$12.11
$14.98

Technical Indicators

Market Signals
Indicator
GDO
ARMP
Relative Strength Index (RSI) 42.35 38.72
Support Level N/A $3.48
Resistance Level $10.86 $5.63
Average True Range (ATR) 0.13 0.40
MACD 0.01 -0.07
Stochastic Oscillator 67.92 17.87

Price Performance

Historical Comparison
GDO
ARMP

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.

Share on Social Networks: